Table 2 Hazard ratios (HR) and their 95% confidence intervals (CI) of death in relation to per standard deviation increase in the frequency of T cell subsets in blood or cerebrospinal fluid, adjusted for age at diagnosis, sex, site of onset, delay in diagnosis, disease progression rate at diagnosis, body mass index (BMI), and the time difference between measurement of BMI and blood sampling, stratified analysis by sex, age, progression rate, and site of onset

From: T cell responses at diagnosis of amyotrophic lateral sclerosis predict disease progression

Cell population out of live cells (%)

No. of patients (deaths)

HR (95% CI)

No. of patients (deaths)

HR (95% CI)

Sex

Female

Male

 CD4+

30 (18)

1.91 (0.94–3.88)

48 (26)

1.53 (0.96–2.45)

 Teff

29 (18)

2.17 (1.024.63)

48 (26)

1.53 (0.96–2.43)

 aTreg/rTreg (ratio)

29 (18)

0.28 (0.110.71)

47 (26)

0.77 (0.47–1.25)

Age

Younger than 67

Older than 67

 CD4+

39 (18)

1.09 (0.67–1.79)

39 (26)

2.32 (1.314.09)

 Teff

39 (19)

1.12 (0.67–1.87)

38 (25)

2.43 (1.334.43)

 aTreg/rTreg (ratio)

38 (18)

0.90 (0.55–1.49)

38 (26)

0.47 (0.260.85)

Progression rate

Slow (<0.45)

Fast (>=0.45)

 CD4+

39 (16)

1.75 (0.94–3.27)

39 (28)

1.76 (1.072.88)

 Teff

39 (17)

1.77 (0.99–3.18)

38 (27)

2.05 (1.163.64)

 aTreg/rTreg (ratio)

38 (17)

0.45 (0.15–1.30)

38 (27)

0.76 (0.44–1.31)

Site of onset

Spinal

Bulbar

 CD4+

43 (20)

1.45 (0.78–2.69)

33 (23)

2.00 (1.183.39)

 Teff

42 (20)

1.42 (0.79–2.56)

33 (23)

2.14 (1.233.71)

 aTreg/rTreg (ratio)

41 (20)

0.89 (0.48–1.65)

33 (23)

0.42 (0.190.90)

  1. HRs that are statistically significant (p < 0.05) are shown in bold format.